Bal Pharma Allots 10 Lakh Warrants to Promoter

• Allottee: Mr. Shailesh Siroya (Promoter)
• Issue Price: Rs 84 per warrant (Rs 2.10 crore upfront received)

Reader Takeaway: Promoter increases stake commitment through preferential warrant issue, strengthening balance sheet for future growth plans.

What just happened

Bal Pharma has officially allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, on a preferential basis. The total issue value of the transaction is Rs 8.40 crore, with the company confirming receipt of the mandatory 25% upfront subscription money, totaling Rs 2.10 crore.

Why this matters

This move represents a direct infusion of capital from the promoter into the company. For retail investors, such actions often signal strong confidence from the company’s management regarding its future prospects. While this does not change the current paid-up equity capital, it sets the stage for a future increase in equity base once the warrants are converted.

Conversion Terms

Each warrant allows the holder to acquire one fully paid-up equity share of Bal Pharma at Rs 84 per share (comprising a Rs 10 face value and a Rs 74 premium). The holder has a window of 18 months from the date of allotment, September 7, 2026, to exercise this conversion right. Any warrants remaining unexercised at the end of this period will lapse, and the upfront payment will be forfeited by the company.

Shareholding Impact

Assuming the full conversion of these 10,00,000 warrants, Mr. Shailesh Siroya’s stake in the company will increase from 17.24% (27,45,459 shares) to approximately 20.89% (37,45,459 shares), based on the current shareholding structure.

What to track next

Investors should monitor the company's financial announcements over the next 18 months to track the actual conversion of these warrants into equity shares, as this will eventually dilute current holdings and increase the total paid-up equity capital of the firm.